This suggests that, among the different subtypes of renal cell carcinoma, MYBBP1A loss is more frequent in chromophobe renal cell carcinoma [42], which could be a suitable subgroup when targeting the oxidative pathways as an alternative therapeutic approach. This evidence concerns the gene MYBBP1A and renal cell carcinoma.